Riskpilot← Back to searchSign inGet full accessJägersrohälsan AB
ABActiveOrg 5591996722Derbyvägen 6 EGeneral medical practice activities · NACE 8621Est. 201920-49 employees
Revenue 2024
SEK 5,5M
+2049% vs 2023
EBITDA margin
-53.1%
-26% vs 2023
Equity ratio
-30.9%
Financial strength
Net profit 2024
SEK -3M
-28% vs 2023
| Revenue | SEK 5,5M | +2049% |
| EBITDA | SEK -2,9M | -26% |
| Net profit | SEK -3M | -28% |
| Total assets | SEK 1,4M | -14% |
| Equity | SEK -442K | -319% |
| Employees | — | — |
Legal name
Jägersrohälsan AB
Org number
5591996722
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
21 mars 2019
Share capital
SEK 50 000
Employees
20-49
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva hälso- och sjukvård samt dämed förenlig verksamhet.
Address
Derbyvägen 6 E
Phone
+4640400800
Email
info@jagersrohalsan.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 | −6 | 0 | 257 | 5 520 |
| Staff expenses | — | — | — | −1 540 | −4 541 |
| EBITDA | — | −7 | −0 | −2 330 | −2 930 |
| Depreciation & amort. | −0 | −0 | — | −16 | −38 |
| EBIT | 0 | −7 | −0 | −2 346 | −2 969 |
| Net financials | — | — | — | −0 | −26 |
| Profit before tax | 0 | −7 | −0 | −2 346 | −2 995 |
| Tax | −0 | −0 | — | — | — |
| Net profit | 0 | −7 | −0 | −2 346 | −2 995 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 56 | 49 | 48 | 1 659 | 1 429 |
| Equity | 56 | 49 | 48 | 202 | −442 |
| Long-term debt | 0 | 0 | — | — | 421 |
| Short-term debt | 0 | 0 | — | 1 457 | 1 450 |
| Total debt | — | — | — | 1 457 | 1 871 |
EBITDA margin
-53.1%
This company
15.8%
Market median
-436% vs market
20202024
Equity ratio
-30.9%
This company
38.2%
Market median
-181% vs market
20202024
Return on equity
-299483800.0%
This company
18.4%
Market median
-1627629448% vs market
20202024
Net profit margin
-54.3%
This company
8.1%
Market median
-770% vs market
20202024
Asset turnover
3.86×
This company
1.12×
Market median
+245% vs market
20202024
Debt / equity
4.23×
This company
0.62×
Market median
-582% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
LK Chief Executive Officer | Chief Executive Officer | 2024 |
AR Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2024 |
AH Chief Auditor | Chief Auditor | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MMS Scandinavia AB
Jägersrohälsan AB Board members of Jägersrohälsan AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Kenneth Kronohage | Chief Executive Officer | 0 companies |
| Anders Rasmus Ahlin | Deputy Chief Executive Officer | 0 companies |
| Annika Helén Larsson | Chief Auditor | 0 companies |
| Bo Magnus Jan-Erik Aycox | Deputy Board Member | 0 companies |
| Thomas Gunnar Petersson | Chairman | 0 companies |